Oragenics Inc  

(Public, NYSEMKT:OGEN)   Watch this stock  
Find more results for OTC:ORNI
2.64
+0.42 (18.92%)
Jul 31 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.17 - 2.90
52 week 0.66 - 2.90
Open 2.22
Vol / Avg. 2.78M/337,974.00
Mkt cap 95.31M
P/E     -
Div/yield     -
EPS -0.15
Shares 36.38M
Beta 0.60
Inst. own 41%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -355.38% -615.95%
Operating margin -356.35% -618.82%
EBITD margin - -615.88%
Return on average assets -49.63% -41.41%
Return on average equity -53.21% -44.24%
Employees 12 -
CDP Score - -

Address

Suite 125, 4902 Eisenhower Blvd
TAMPA, FL 33634
United States - Map
+1-813-2867900 (Phone)
+1-813-2867904 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oragenics, Inc. is focused on the discovery, development and commercialization of a variety of technologies associated with oral health, broad spectrum antibiotics and other general health benefits. The Company is focused on antibiotics against infectious disease and probiotics for oral health in humans and pets. It also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. Its SMaRT Replacement Therapy is designed to be a treatment applied to the teeth that has the potential to offer protection against dental caries, or tooth decay.

Officers and directors

Frederick W. Telling Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Michael O'Keefe Sullivan CPA Interim Principal Executive Officer, Chief Financial Officer, Treasurer, Secretary
Age: 58
Bio & Compensation  - Reuters
Alan W. Dunton M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Christine L. Koski Independent Director
Age: 58
Bio & Compensation  - Reuters
Robert C. Koski Independent Director
Age: 56
Bio & Compensation  - Reuters
Charles L. Pope CPA Independent Director
Age: 63
Bio & Compensation  - Reuters